Skip to main content
. 2020 Jul 20;2(9):1377–1387. doi: 10.1007/s42399-020-00417-7

Table 1.

Summary of systemic manifestations and possible pathological mechanisms

Body systems Clinical manifestations Imaging/Electrocardiogram (ECG) findings Blood test anomalies Pathological mechanisms/findings
Respiratory system

• Cough

• Sputum production

• Shortness of breath

• Respiratory distress and failure (acute respiratory distress syndrome)

• Ground-glass opacities and pulmonary consolidation or exudation (thoracic CT-scan)

• Hyaline membrane formation at the alveolar level (acute stage)

• Interstitial edema

• Fibroblast proliferation

• Altered alveolar-capillary exchange

• Pulmonary thrombosis

Cardiovascular system

• Acute coronary syndrome

• Acute heart failure

• Myocarditis

• Cardiac arrhythmias

• Thromboembolic events

• QT prolongation

Torsades de pointes (TdP); seen on ECG

• Infection and acute respiratory distress (for acute heart failure)

• Inflammation (for myocarditis and thromboembolism)

• Hypoxia, immobilization, disseminated intravascular coagulation (for thromboembolic events)

• Myocardial injury, renal failure, liver failure, hypokalemia (for TdP)

Urinary system

• Acute kidney injury

• Isolated urine abnormalities (proteinuria, hematuria)

• Kidney inflammatory signs (CT-scan) • Viral-induced kidney inflammation
Hematopoietic system • Signs of anemia.

• Low hemoglobin levels

• Leukocytosis

• Neutrophilia

• Increased neutrophils/lymphocytes ratio

• Low eosinophil, monocytes, lymphocytes, and platelet counts

• Raised erythrocyte sedimentation rate

• Increased C-reactive protein

• High ferritin

• High procalcitonin levels

• “Cytokine storm” with high levels of interleukins 1, 2R, 6, 7, and 17; tumor necrosis factor alpha; monocyte chemoattractant protein 1; macrophage inflammatory protein 1α; and interferon-γ inducible protein 10

• Increase of prothrombotic markers: D-dimers, fibrinogen and prothrombin levels and partial activated thromboplastin time

• Viral-induced hyperinflammation

• Spleen enlargement/atrophy

• Diffused lymphoid tissue atrophy

• Immune reaction in response to the infectious process (for leukocytosis and neutrophilia)

• Virus-induced apoptosis, increased lymphocyte activation, and inhibition of lymphocyte proliferation (for lymphopenia)

• Platelet consumption (for thrombocytopenia)

Gastrointestinal tract system plus hepatic and pancreatic involvement

• Diarrhea

• Vomiting

• Abdominal pain

• Focal enlargement of the pancreas or dilatation of the pancreatic duct, without acute necrosis

• Raised transaminases levels

• Increased total bilirubin

• Low albumin levels

• Increased levels of pancreatic enzymes

• Alteration of intestinal permeability with resultant malabsorption, gut microbiome alterations, intestinal inflammation mediated by ACE2 receptors (for diarrhea)

• Viral binding on ACE2 cholangiocytes (for liver dysfunction)

• Microvascular steatosis, mild lobular and portal activity

• Drug-induced liver injury by lopinavir/ritonavir combination, hydroxychloroquine, through reactive metabolites or idiosyncrasy

• Direct effect of the virus on pancreatic tissues, systemic inflammatory response and drug-related pancreatic injury

Nervous system

• Headaches

• Impaired consciousness (and other encephalitis signs such as seizures)

• Motor deficit (if stroke)

• Smell and taste alterations

• Visual impairment

• Neuralgia

• Agitation

• Mental ill health (stress, anxiety, depression, suicidal intentions, isolation, social exclusion and stigma)

• CT-scan signs of cerebrovascular lesions

• Direct infection injury demonstrated by the presence of the virus in the cerebrospinal fluid

• Cytokine dysregulation

• Demyelinating reactions (mainly for peripheral nervous system signs)

• Brain hypoxia

• Peripheral immune cells transmigration

• Post-infectious autoimmunity

• Microbial translocation through the gut-brain axis

• Drug adverse effects (i.e., chloroquine and agitation)

Musculoskeletal system

• Muscle pain

• Muscle weakness

• Joint pain

• Cytokine-mediated sensitization of sensitive receptors on the muscular fibers (for muscle weakness and pain)

• Articular deposit of cytokines (for joint pain)

ACE 2 angiotensin-converting enzyme 2, CT-scan computed tomography scan, ECG electrocardiogram, TdP Torsades de pointes